Does levodopa slow or hasten the rate of progression of Parkinson's disease?

Journal of Neurology

Volumn 252, Issue SUPPL. 4, 2005, Pages

  Fahn, Stanley ^a  

^a NEUROLOGICAL INSTITUTE   (United States)

Author keywords

Controlled clinical trial; Dopamine transporter imaging; Levodopa; Natural history; Parkinson's disease; Toxicity

Indexed keywords

CARBIDOPA PLUS LEVODOPA; PLACEBO; TRACER;

CONFERENCE PAPER; CONTROLLED STUDY; CORPUS STRIATUM; DISEASE COURSE; DISEASE DURATION; DISEASE EXACERBATION; DOSE RESPONSE; DRUG DOSE REGIMEN; DYSKINESIA; GAIT DISORDER; HUMAN; MAJOR CLINICAL STUDY; NAUSEA; NEUROIMAGING; ON OFF PHENOMENON; PARKINSON DISEASE; PRIORITY JOURNAL; RANDOMIZATION; RATING SCALE; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TREATMENT OUTCOME;

ANTIPARKINSON AGENTS; BRAIN; CARBIDOPA; DISEASE PROGRESSION; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; HUMANS; LEVODOPA; PARKINSON DISEASE; RANDOMIZED CONTROLLED TRIALS; TREATMENT OUTCOME;

EID: 26444597591     PISSN: 03405354     EISSN: 14321459     Source Type: Journal    
DOI: 10.1007/s00415-005-4008-5     Document Type: Conference Paper

References (33)

1. th edn, Lippincott Williams and Wilkins, Philadelphia, pp 828-846
2. Riederer P, Wuketich S (1976) Time course of nigrostriatal degeneration in Parkinson's disease. J Neural Transm 38:277-301
3. Hornykiewicz O (1982) Brain neurotransmitter changes in Parkinson's disease. In: Marsden CD, Fahn S (eds) Movement Disorders. Butterworth Scientific, London, pp 41-58
4. Cotzias GC, Van Woert MH, Schiffer LM (1967) Aromatic amino acids and modification of parkinsonism. N Engl J Med 276:374-379
5. Cotzias GC, Papavasiliou PS, Gellene R (1969) Modification of parkinsonism - chronic treatment with L-dopa. N Engl J Med 280:337-345
6. Miyasaki JM, Martin W, Suchowersky O, Weiner WJ, Lang AE (2002) Practice parameter: Initiation of treatment for Parkinson's disease: An evidence-based review. Neurology 58:11-17
7. Fahn S (1989) Adverse effects of levodopa in Parkinson's disease. In: Calne DB (ed) Drugs for the treatment of Parkinson's Disease. Handbook of Experimental Pharmacology 88. Springer, Berlin, pp 385-409
8. Fahn S (1999) Parkinson disease, the effect of levodopa, and the ELLDOPA trial. Arch Neurol 56:529-535
9. Fahn S (1996) Is levodopa toxic? Neurology 47:S184-S195
10. Fahn S (1997) Levodopa-induced neurotoxicity: Does it represent a problem for the treatment of Parkinson's disease? CNS Drugs 8:376-393
11. Agid Y (1998) Levodopa: is toxicity a myth? Neurology 50(4):858-863
12. Weiner WJ (1999) The initial treatment of Parkinson's disease should begin with levodopa. Mov Disord 14(5):716-724
13. Factor SA (2000) The initial treatment of Parkinson's disease. Mov Disord 15(2):360-361
14. Parkinson Study Group (2002) Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson disease progression. JAMA 287(13):1653-1661
15. Parkinson Study Group (2004) Pramipexole vs levodopa as initial treatment for Parkinson disease - A 4-year randomized controlled trial. Arch Neurol 61(7):1044-1053
16. Whone AL, Watts RL, Stoessl AJ, et al. (2003) Slower progression of Parkinson's disease with ropinirole versus levodopa: The REAL-PET study. Ann Neurol 4(1):93-101
17. Rascol O, Brooks DJ, Korczyn AD, et al. (2000) A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa. 056 Study Group. N Engl J Med 342(20):1484-1491
18. Morrish PK, Sawle GV, Brooks DJ (1996) An [F-18]dopa-PET and clinical study of the rate of progression in Parkinson's disease. Brain 119:585-591
19. Marek K, Jennings D, Seibyl J (2002) Do dopamine agonists or levodopa modify Parkinson's disease progression? Eur J Neurol 9(Suppl 3):15-22
20. Albin RL, Frey KA (2003) Initial agonist treatment of Parkinson disease: a critique. Neurology 60(3):390-394
21. Dauer W, Przedborski S (2003) Parkinson's Disease: Mechanisms and Models. Neuron 39:889-909
22. Vila M, Przedborski S (2003) Targeting programmed cell death in neurodegenerative diseases. Nat Rev Neurosci 4(5):365-375
23. Fahn S, Sulzer D (2004) Neurodegeneration and neuroprotection in Parkinson disease. NeuroRx 1:139-154
24. Parkinson Study Group (2004) Levodopa and the progression of Parkinson's disease. N Engl J Med 351(24):2498-2508
25. Parkinson Study Group (1993) Effects of tocopherol and deprenyl on the progression of disability in early parkinson's disease. N Engl J Med 328:176-183
26. Parkinson Study Group (1996) Effect of lazabemide on the progression of disability in early Parkinson's disease. Ann Neurol 40:99-107
27. Shults CW, Oakes D, Kieburtz K, Beal MF, Haas R, Plumb S, Juncos BL, Nutt J, Shoulson I, Carter J, Kompoliti K, Perlmutter JS, Reich S, Stern M, Watts RL, Kurlan R, Molho E, Harrison M, Lew M (2002) Effects of coenzyme Q(10) in early Parkinson disease - Evidence of slowing of the functional decline. Arch Neurol 59(10):1541-1550
28. Parkinson Study Group (2004) A controlled, randomized, delayed-start study of rasagiline in early Parkinson disease. Arch Neurol 61(4):561-566
29. de Jong GJ, Meerwaldt JD, Schmitz PIM (1987) Factors that influence the occurrence of response variations in Parkinson's disease. Ann Neurol 22:4-7
30. Quinn N, Critchley P, Marsden CD (1987) Young onset Parkinson's disease. Mov Disord 2:73-91
31. Blin J, Bonnet A-M, Agid Y (1988) Does levodopa aggravate Parkinson's disease? Neurology 38:1410-1416
32. Roos RAC, Vredevoogd CB, van der Velde EA (1990) Response fluctuations in Parkinson's disease. Neurology 40: 1344-1346
33. Cedarbaum JM, Gandy SE, McDowell FH (1991) Early initiation of levodopa treatment does not promote the development of motor response fluctuations, dyskinesias, or dementia in Parkinson's disease. Neurology 41: 622-629